NovoCure Limited (NVCR)
- Previous Close
17.10 - Open
17.17 - Bid 12.51 x 200
- Ask 21.41 x 200
- Day's Range
16.67 - 17.62 - 52 Week Range
14.17 - 34.13 - Volume
770,115 - Avg. Volume
923,269 - Market Cap (intraday)
1.961B - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-1.51 - Earnings Date Apr 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.57
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
www.novocure.comRecent News: NVCR
View MorePerformance Overview: NVCR
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVCR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVCR
View MoreValuation Measures
Market Cap
1.96B
Enterprise Value
1.73B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.07
Price/Book (mrq)
5.42
Enterprise Value/Revenue
2.78
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.41%
Return on Assets (ttm)
-8.64%
Return on Equity (ttm)
-45.52%
Revenue (ttm)
621.71M
Net Income Avi to Common (ttm)
-164.19M
Diluted EPS (ttm)
-1.51
Balance Sheet and Cash Flow
Total Cash (mrq)
929.13M
Total Debt/Equity (mrq)
192.49%
Levered Free Cash Flow (ttm)
16.94M